RiaSTAP®: Instructions for use

RiaSTAP® Fibrinogen Concentrate

1 Prepare RiaSTAP®

Diluent Vial

Product Vial

- Ensure that the diluent (Sterile Water for Injection) and RiaSTAP® product vials are at room temperature.
- Wash hands or use gloves before reconstituting (mixing) the product.
- Remove the cap from the RiaSTAP® vial to expose the rubber stopper. Clean the surface of the stopper with an antiseptic solution and let it dry.

2 Transfer Diluent into Product Vial

Fig. A Fig. B

Using an appropriate transfer device or a syringe, transfer 50 mL of diluent (Fig. A) into the RiaSTAP® vial (Fig. B).

3 Dissolve Product

Gently swirl the vial to ensure the product is fully dissolved (generally 5 to 10 minutes). Do not shake the vial; this will cause it to foam.

4 Insert Dispensing Pin

Open the plastic blister containing the Mini-Spike® Dispensing Pin and insert it into the stopper of the vial with the reconstituted RiaSTAP®.

5 Remove Cap

After the dispensing pin is inserted, remove the cap. After the cap is removed, do not touch the exposed surface.

6 Screw Syringe onto Filter

Open the blister with the Pall® Syringe Filter and screw the syringe onto the filter.

7 Screw Syringe onto Dispensing Pin

Screw the syringe with the mounted filter onto the dispensing pin.

8 Draw up Product

Draw the reconstituted product into the syringe.

9 Administer Product

When completed, remove the filter, dispensing pin and empty vial from the syringe, dispose of properly, and administer the product immediately using a separate injection/infusion line.

After reconstitution:

- **The RiaSTAP® solution should be colourless and clear to slightly opalescent.**
- **Do not use if the solution is cloudy or contains particles.**
- **RiaSTAP® is stable for 8 hours when stored at room temperature and should be administered within this time period.**

- **Do not use RiaSTAP® beyond the expiration date.**
- **RiaSTAP® contains no preservative.**

RiaSTAP® (fibrinogen concentrate [Human], FCH) is indicated for the treatment of congenital fibrinogen deficiency which comprises congenital afibrinogenemia and hypofibrinogenemia.

Please consult the Product Monograph at cslbehring.ca/products/product-list for important information relating to contraindications, warnings and precautions, adverse reactions, drug interactions, dosing, and conditions of clinical use which has not been discussed in this piece. The Product Monograph is also available by calling 1-866-773-7721.

CSL Behring

RSP2023050058EN